RecruitingPhase 4NCT06765265
Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
Sponsor
King Edward Medical University
Enrollment
152 participants
Start Date
Jan 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria2
- Acute Coronary Syndrome
- OH-Vitamin D levels between 30-70ng/ml
Exclusion Criteria8
- Hypercalcemia
- hypocalcemia
- pregnancy
- lactation
- hypersensitivity to statins
- hypothyroidism
- Deranged LFTs \& RFTs
- Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRosuvastatin 20 mg/day
Rosuvastatin 20 mg / Day for 24 weeks
DRUGAtorvastatin 40 mg
Atorvastatin 40mg / Day for 24 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06765265
Related Trials
Point-of-Care Troponin Testing in the Emergency Department
NCT068458261 location
A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices
NCT068900131 location
Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients
NCT068133391 location
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT0692773941 locations
Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea
NCT072688592 locations